Literature DB >> 526920

Quantitative experimental evaluation of adriamycin cardiotoxicity in the mouse.

C Bertazzoli, O Bellini, U Magrini, M G Tosana.   

Abstract

Adriamycin cardiotoxicity was morphologically evaluated in mice treated iv ten times at three dose levels which were equal to fixed fractions of the LD50. Good correlation between the degenerative heart lesions, scored according to a nonparametric scoring system, and the doses was found and allowed calculation of a median cumulative cardiotoxic dose of 36.4 mg/kg of body weight (121.5 mg/m2). The method is suitable for quantitative screening of the potential cardiotoxicity of new anthracycline analogs under standardized conditions.

Entities:  

Mesh：

Substances：

Year:  1979        PMID： 526920

Source DB:  PubMed          Journal:  Cancer Treat Rep        ISSN： 0361-5960


  21 in total

1.  Sirtuin 1 ablation in endothelial cells is associated with impaired angiogenesis and diastolic dysfunction.

Authors:  Julien Maizel; Sandhya Xavier; Jun Chen; Chi Hua Sarah Lin; Radovan Vasko; Michael S Goligorsky
Journal:  Am J Physiol Heart Circ Physiol       Date:  2014-09-19       Impact factor: 4.733

2.  Aerobic Exercise During Early Murine Doxorubicin Exposure Mitigates Cardiac Toxicity.

Authors:  Fei Wang; Brian Iskra; Eugenie Kleinerman; Claudia Alvarez-Florez; Thomas Andrews; Angela Shaw; Joya Chandra; Keri Schadler; Gregory J Aune
Journal:  J Pediatr Hematol Oncol       Date:  2018-04       Impact factor: 1.289

3.  Accumulation and metabolism of new anthracycline derivatives in the heart after IV injection into mice.

Authors:  D Deprez-de Campeneere; R Baurain; A Trouet
Journal:  Cancer Chemother Pharmacol       Date:  1982       Impact factor: 3.333

Review 4.  Myocardial diseases of animals.

Authors:  J F Van Vleet; V J Ferrans
Journal:  Am J Pathol       Date:  1986-07       Impact factor: 4.307

5.  Pixantrone (BBR 2778) has reduced cardiotoxic potential in mice pretreated with doxorubicin: comparative studies against doxorubicin and mitoxantrone.

Authors:  Ennio Cavalletti; Luca Crippa; Patrizia Mainardi; Norberto Oggioni; Rosanna Cavagnoli; Ornella Bellini; Franca Sala
Journal:  Invest New Drugs       Date:  2007-06       Impact factor: 3.850

6.  Chronic effects of a novel synthetic anthracycline derivative (SM-5887) on normal heart and doxorubicin-induced cardiomyopathy in beagle dogs.

Authors:  T Noda; T Watanabe; A Kohda; S Hosokawa; T Suzuki
Journal:  Invest New Drugs       Date:  1998       Impact factor: 3.850

7.  Reduced cardiotoxicity of doxorubicin given in the form of N-(2-hydroxypropyl)methacrylamide conjugates: and experimental study in the rat.

Authors:  T K Yeung; J W Hopewell; R H Simmonds; L W Seymour; R Duncan; O Bellini; M Grandi; F Spreafico; J Strohalm; K Ulbrich
Journal:  Cancer Chemother Pharmacol       Date:  1991       Impact factor: 3.333

8.  Chronic cardiotoxicity of anticancer anthracyclines in the rat: role of secondary metabolites and reduced toxicity by a novel anthracycline with impaired metabolite formation and reactivity.

Authors:  Giuseppe Sacco; Rossella Giampietro; Emanuela Salvatorelli; Pierantonio Menna; Nicoletta Bertani; Gallia Graiani; Fabio Animati; Cristina Goso; Carlo A Maggi; Stefano Manzini; Giorgio Minotti
Journal:  Br J Pharmacol       Date:  2003-06       Impact factor: 8.739

9.  Doxorubicin binds in a cooperative manner to myocardial cells. Two binding sites.

Authors:  K Wassermann; E Steiness
Journal:  Cancer Chemother Pharmacol       Date:  1986       Impact factor: 3.333

10.  Timing of treatment with ICRF-187 and its effect on chronic doxorubicin cardiotoxicity.

Authors:  E H Herman; V J Ferrans
Journal:  Cancer Chemother Pharmacol       Date:  1993       Impact factor: 3.333
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.